- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
36
36 companies
Axsome Therapeutics
Market Cap: US$9.4b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$186.42
7D
1.2%
1Y
78.9%
Madrigal Pharmaceuticals
Market Cap: US$12.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$518.74
7D
-1.1%
1Y
62.1%
Zevra Therapeutics
Market Cap: US$615.9m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.11
7D
-2.8%
1Y
39.6%
Travere Therapeutics
Market Cap: US$3.7b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$40.82
7D
3.2%
1Y
131.5%
Syndax Pharmaceuticals
Market Cap: US$1.9b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$21.00
7D
-11.8%
1Y
57.9%
Insmed
Market Cap: US$31.2b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$143.83
7D
0.7%
1Y
108.6%
Rhythm Pharmaceuticals
Market Cap: US$5.8b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$85.18
7D
-3.0%
1Y
42.3%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.96
7D
-5.1%
1Y
18.7%
Aldeyra Therapeutics
Market Cap: US$102.3m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.60
7D
-11.1%
1Y
-39.6%
ARS Pharmaceuticals
Market Cap: US$834.1m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.30
7D
1.5%
1Y
-43.3%
Pelthos Therapeutics
Market Cap: US$77.2m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$23.20
7D
0.9%
1Y
69.3%
Capricor Therapeutics
Market Cap: US$2.0b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$33.86
7D
-2.1%
1Y
155.0%
AC Immune
Market Cap: US$303.6m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.97
7D
-3.3%
1Y
78.9%
Arcutis Biotherapeutics
Market Cap: US$2.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$22.86
7D
-5.5%
1Y
55.3%
CG Oncology
Market Cap: US$5.9b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$69.89
7D
5.4%
1Y
224.8%
Kiniksa Pharmaceuticals International
Market Cap: US$3.3b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$43.05
7D
-5.0%
1Y
109.4%
Vera Therapeutics
Market Cap: US$2.9b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$40.27
7D
-7.3%
1Y
80.3%
Neurocrine Biosciences
Market Cap: US$13.2b
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
NBIX
US$130.19
7D
1.4%
1Y
23.1%
Belite Bio
Market Cap: US$6.6b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$164.45
7D
4.0%
1Y
176.0%
Verrica Pharmaceuticals
Market Cap: US$111.7m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.49
7D
4.5%
1Y
39.1%
SIGA Technologies
Market Cap: US$323.1m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.53
7D
-2.4%
1Y
-30.1%
BeOne Medicines
Market Cap: US$34.6b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$299.81
7D
-6.5%
1Y
17.0%
Praxis Precision Medicines
Market Cap: US$9.4b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$329.60
7D
2.9%
1Y
815.6%
Unicycive Therapeutics
Market Cap: US$194.6m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$7.35
7D
6.5%
1Y
14.8%
Gyre Therapeutics
Market Cap: US$705.9m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.44
7D
-5.8%
1Y
-18.4%
Benitec Biopharma
Market Cap: US$443.9m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$12.70
7D
-5.6%
1Y
-8.6%
Fennec Pharmaceuticals
Market Cap: US$230.3m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.66
7D
5.7%
1Y
17.0%
Mirum Pharmaceuticals
Market Cap: US$5.7b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$91.95
7D
-4.1%
1Y
127.2%
Journey Medical
Market Cap: US$137.7m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$5.13
7D
-0.8%
1Y
-32.1%
Fortress Biotech
Market Cap: US$72.5m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.23
7D
-5.1%
1Y
34.3%
Geron
Market Cap: US$993.4m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.50
7D
-11.2%
1Y
5.6%
Dyadic International
Market Cap: US$30.2m
A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.
DYAI
US$0.87
7D
-1.3%
1Y
-28.4%
Prothena
Market Cap: US$577.1m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$10.73
7D
2.0%
1Y
11.2%
Inovio Pharmaceuticals
Market Cap: US$93.4m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$1.14
7D
-1.7%
1Y
-40.6%
Protagonist Therapeutics
Market Cap: US$6.7b
Operates as a discovery and development company in the United States.
PTGX
US$102.62
7D
-1.1%
1Y
128.8%
Legend Biotech
Market Cap: US$4.8b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$23.99
7D
13.8%
1Y
-29.9%